---
title: '<sup>177</sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor
  therapy for taxane-naive patients with progressive metastatic castration-resistant
  prostate cancer (PSMAfore): a phase 3, randomised, controlled trial'
date: '2024-09-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39293462/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240919194323&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: [^(177)Lu]Lu-PSMA-617 (^(177)Lu-PSMA-617) prolongs radiographic
  progression-free survival and overall survival in patients with metastatic castration-resistant
  prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI)
  and taxane therapy. We aimed to investigate the efficacy of ^(177)Lu-PSMA-617 in
  patients with taxane-naive metastatic castration-resistant prostate ...'
disable_comments: true
---
BACKGROUND: [^(177)Lu]Lu-PSMA-617 (^(177)Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of ^(177)Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate ...